



Contacts: Tularik Inc.
Alicia Williams (Investors/Media), 650-825-7322

Tularik to Present at the 22nd Annual JPMorgan Healthcare Conference

South San Francisco, Calif. –(Business Wire) – January 6, 2004-- Tularik Inc. (Nasdaq:TLRK) announced today that David V. Goeddel, Ph.D., Chief Executive Officer, will present at the 22nd Annual JPMorgan Healthcare Conference on Wednesday, January 14, 2004 at 1:30 p.m. Pacific Time at The Westin St. Francis Hotel in San Francisco, California.

The presentation will be webcast and may be accessed at the Company's website, www.tularik.com, under the Investors/Media tab. In addition, an archived version of the webcast will be available on the Company's website for 30 days.

About Tularik

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, immunology and metabolic disease. The Company currently has four drug candidates in clinical trials. In the cancer area, Tularik is currently conducting a pivotal study of T67 for the treatment of hepatocellular carcinoma (HCC) and Phase 2 trials with T607 for the treatment of HCC, ovarian cancer, gastric cancer and esophageal cancer. T487 for the treatment of psoriasis is in Phase 2 trials. T487 for the treatment of rheumatoid arthritis, and T131 for the treatment of type 2 diabetes, are moving into Phase 2 trials. For more information, visit Tularik's Internet website at www.tularik.com.